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Background: Burkitt ? s lymphoma is an aggressive malignancy with high risk of metastasis to extranodal sites,
such as bone marrow and central nervous system. The prognosis of metastatic Burkitt ? s lymphoma is poor.
Here we sought to identify a role of histone deacetylase 6 (HDAC6) in the metastasis of Burkitt? s lymphoma cells.
Methods: Burkitt? s lymphoma cells were pharmacologically treated with niltubacin, tubacin or sodium butyrate (NaB)
or transfected with siRNAs to knock down the expression of HDAC6. Cell migration and invasion ability were measured
by transwell assay, and cell cycle progression was analyzed by flow cytometry. Cell adhesion and proliferation was
determined by CellTiter-Glo luminescent cell viability assay kit. Cell morphological alteration and microtubule stability
were analyzed by immunofluorescence staining. Effect of niltubacin, tubacin and NaB on acetylated tubulin and siRNA
efficacy were measured by western blotting.
Results: Suppression of histone deacetylase 6 activity significantly compromised the migration and invasion of Burkitt? s
lymphoma cells, without affecting cell proliferation and cell cycle progression. Mechanistic study revealed that HDAC6
modulated chemokine induced cell shape elongation and cell adhesion probably through its action on microtubule
dynamics.
Conclusions: We identified a critical role of HDAC6 in the metastasis of Burkitt? s lymphoma cells, suggesting that
pharmacological inhibition of HDAC6 could be a promising strategy for the management of metastatic Burkitt? s
lymphoma.
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Burkitt? s lymphoma (BL) as a highly aggressive B-cell malig-
nancy, usually occurs in adolescent as well as in patients
with immune defect. Endemic BL is the most common
variant and prevails in Africa where almost all the patients
are found with Epstein-Barr Virus (EBV) infection [1,2]. Be-
sides, there are two other BL variants: sporadic BL which
accounts for about 30-50% of childhood lymphomas in the
developed countries, and HIV infection caused immune-
deficient associated type [3]. BL grows rapidly, potentially
doubling in size every day, which leads to its sensitivity to
chemotherapeutic agents. Currently most of the childhood
BL is effectively managed with the cyclical intensive chemo-
therapy [4]. However, another feature of BL is its high
aggression, occasionally disseminates to bone marrow* Correspondence: songyuqin622@163.com; zhu-jun@bjcancer.org
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unless otherwise stated.(BM) and central nervous system (CNS), contributing
to poor prognosis in clinics [5]. Therefore, attempts to ex-
plore better regimens to inhibit the metastasis of BL is ur-
gently needed.
Histone deacetylases (HDACs) are a superfamily com-
prising of 18 proteins, which regulate gene expression
through deacetylation of histones to produce a highly
compact chromatin structure [6,7]. Besides, HDACs inter-
act with many non-histone substrates to regulate diverse
cellular activities, including cell division, cell motility, and
angiogenesis [8,9], making targeting HDACs being a
promising approach for treatment of various malignancy.
Several HDAC inhibitors have demonstrated excellent in-
hibitory effects on tumor growth [10], for instance, pano-
binostat, a pan-HDAC inhibitor, hold great promise in
several hematological malignancy including cutaneous T-
cell lymphoma, Hodgkin lymphoma, and B-cell lymphoma
in both preclinical study and clinical trials [11]. However,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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vere adverse effects, such as thrombocytopenia are also
observed. Therefore, elucidating the role of each HDAC
member in tumors could shed light to the development of
better regimens against cancers. HDAC6 is a unique
member of HDAC family, which is localized predomin-
antly in the cytoplasm [12]. Unlike the other HDAC mem-
bers, HDAC6 bears two catalytic HDAC domains and has
minimal effect on cell cycle related gene expression and
cell proliferation [13], making its role in malignant tumors
elusive. In this study, we adopted tubacin, niltubacin (dea-
cetylase inactive tubacin derivatives), and sodium butyrate
(NaB) to elucidate the role of HDAC6 in BL. Tubacin is a
specific inhibitor of HDAC6, while NaB is a HDAC activ-
ity which lacks activity on HDAC6 [12]. Our data demon-
strated that inhibition of HDAC6 activity significantly
suppressed SDF-1α induced cell shape elongation and cell
adhesion, thereby leading to impaired cell motility without
affecting cell proliferation.
Results
Firstly we investigated the role of HDAC6 in BL cell mo-
tility. Raji cells cells were plated into the inserts that
were precoated with or without Fibronectin for invasion
and migration study, respectively. Invaded or migratedFigure 1 Inhibition of HDAC6 significantly compromises the motility
NaB, tubacin or niltubacin were seeded into the inserts which were coated
were analyzed by FCAS. (B) Raji cells were transfected with siRNAs for 48 h
(C) Raji cells transfected with siRNAs were seeded into transwell inserts for
of Namalwa cells treated with DMSO, NaB, tubacin or niltubacin. (E) Raji ce
SDF-1α for 3 hours, and then cells were seeded to the wells which were p
and adherent cells were measured by CellTiter-Glo luminescent cell viability a
ns, not significant.cells were collected 12 hours later and analyzed by FACS.
As shown in Figure 1A, tubacin and niltubacin treatment
remarkably compromised SDF-1α induced motility of BL
cells, whereas DMSO or NaB exposure had no obvious ef-
fect on cell motility. To confirm the observation we
knocked down the expression of HDAC6 by using siRNA
(Figure 1B), and found that siHDAC6 treatment mark-
edly decreased the migration and invasion of Raji cells
(Figure 1C). To examine the generalization role of HDAC6
in BL cell motility, we assayed on another BL Namalwa
cells. Consistently, similar results were observed in
Namalwa cells (Figure 1D). As cell attachment to endo-
thelium or extracellular matrix (ECM) is prerequisite for
malignant cell infiltration to the destined sites, we exam-
ined whether HDAC6 regulates cell motility via its action
on cell adhesion. SDF-1α stimulation significantly en-
hanced the cell adhesion to Fibronectin, whereas tubacin
or niltubacin exposure markedly compromised SDF-1α in-
duced cell adhesion (Figure 1E). By contrast, NaB treat-
ment showed little reduction of cell adhesion (Figure 1E).
Taken together, these findings reveal the HDAC6 is critical
for SDF-1α induced cell motility and cell adhesion.
Cell motility is a complex process which is exquisitely or-
chestrated and involves a multiple of proteins which collab-
orate with cytoskeletons to facilitate directed movement.and adhesion of BL cells. (A) Raji cells cells pretreated with DMSO,
without or with Fibronectin. 12 hour later, cells in the lower chambers
ours, and the knockdown efficacy was determined by western blotting.
migration and invasion detection. (D) Migration and invasion analysis
lls treated with DMSO, NaB, tubacin or niltubacin were stimulated with
recoated with Fibronectin. Cells were allowed to adhere for 30 minutes,
ssay kit. *, **, *** indicate P <0.05, 0.01, 0.001 versus DMSO, respectively;
Figure 3 HDAC6 does not affect the cell proliferation and cell
cycle progression. (A) Raji cells were treated with DMSO, NaB, or
tubacin for the indicated time, and cell viability was determined by
CellTiter-Glo luminescent cell viability assay. (B) Cell cycle analysis of
Raji cells treated with DMSO, NaB, or tubacin. (C) Experiments were
performed as in panel B, and the percentage of cells in G1, S, and G2/M
phases was calculated. *, P < 0.05 versus control; ns, not significant.
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the movement direction, accompanied with cell shape
elongation and asymmetry distribution of cellular mole-
cules. To test whether HDAC6 regulates lymphoma cell
motility through affecting cell shape elongation, Raji cells
pretreated with DMSO, NaB, tubacin, or niltubacin were
stimulated with SDF-1α to induce cell movement. Inter-
estingly, cells became elongated in the presence of SDF-1α
(Figure 2A, left panels). By contrast, compared with NaB
or niltubacin treatment, tubacin exposure remarkably inhib-
ited the SDF-1α induced cell shape elongation (Figure 2A,
right panels). Collectively, these data suggest that HDAC6
activity is essential for chemokine induced cell shape
elongation, which is critical for cell polarity and motility.
HDAC inhibitors dramatically shrink several types of
cancers in clinical trials. We thus investigated the in-
volvement of HDAC6 in lymphoma cell growth. Raji
cells were treated with DMSO, NaB, or tubacin for the
indicated time and cell viability was measured. As shown
in Figure 3A, NaB treatment significantly suppressed the
proliferation of BL Raji cells, however, little cytotoxicity
was observed in the tubacin treatment group. To confirm
the results observed in cell proliferation, we analyzed the
effect of HDAC6 on cell cycle progression. Raji cells were
stained with PI for DNA content analysis. NaB treatment
decreased the percentage of cells at G1 phase and arrested
cells at G2/M phase, whereas DMSO or tubacin treatment
did not affect the percentage of cells at G1, S, and G2/M
phases compared with that of the NaB treatment group
(Figure 3B). Collectively, these data reveal that HDAC6
activity is independent from HDAC-mediated cell prolifer-
ation and cell cycle progression.
As microtubules are the key component regulator of
cell motility, we then examined whether HDAC6 regu-
lates Raji cell elongation, motility, and adhesion throughFigure 2 The role of HDAC6 in SDF-1α induced cell shape elongation. Raji cells pretreated with DMSO, NaB,tubacin or niltubacin for 3 hours
were stimulated with SDF-1α, and then cells were immunostained with anti-α-tubulin (green) antibody and DAPI (blue).
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and B, tubacin exposure remarkably elevated the level of
acetylated microtubules, whereas NaB or niltubacin treat-
ment did not increase the microtubule acetylation. By
immunostaining of acetylated microtubules we confirmed
the observation in immunoblotting, tubacin treatment
significantly contributed to enhanced microtubule acetyl-
ation in cells (Figure 4C). To elucidate whether the regula-
tion of microtubule dynamics is dependent on the tubulin
deacetylase activity or HDAC6 itself binding to the micro-
tubules, we tested the microtubule stability of HDAC6-
depleted cells in cold-induced depolymerizing condition.
Depletion of HDAC6 did not promote the microtubule
stability (Figure 4D), whereas pharmacological inhibition
of HDAC6 with tubacin resulted in an increase in
microtubule stability against cold-induced microtubule
disassembly (Figure 4E). To sum up, these data reveal
an important role of HDAC6 in chemokine induced
cell shape elongation and cell motility, and implicates
that HDAC6-mediated microtubule dynamics might beFigure 4 Suppression of HDAC6 markedly enhances the acetylation o
tubacin were lyzed and the acetylated tubulin was determined by western
ratio of acetylated tubulin to total tubulin was determined. (C) Raji cells tre
anti-α-tubulin (green), anti-acetylated tubulin (red) antibodies and DAPI (blu
to depolymerize microtubules and then cells were fixed and immunostaine
(E) Raji cells pretreated with DMSO, NaB, niltubacin or tubacin for 24 hours w
with antibodies against α-tubulin (green) and acetylated tubulin (red), and DAthe underlying mechanism of cell shape elongation and
motility.
Discussion
BL is an aggressive B cell malignant disease with high
risk of metastasis to extranodal sites. The prognosis for
BL with involvement of BM and CNS is poor. Thus, at-
tempts to explore agents to inhibit the metastasis of BL
is greatly needed. In this study, we found that HDAC6
plays a crucial role in SDF-1α induced cell morpho-
logical changes. It is noteworthy that cell polarization to-
wards elongated shape is prerequisite for cell migration
and invasion [14,15]. Further study confirmed that sup-
pression of HDAC6 significantly restrained the motility
of Raji cells. These findings thus suggest that targeting
HDAC6 might be a potential strategy for management
of metastatic BL.
HDAC inhibitors have been proved to be effective for
several types of cancer, immune disorders, and neurodegen-
erative diseases [16-18]. Currently almost all the extensivelyf microtubules. (A) Raji cells treated with DMSO, NaB, niltubacin, or
blotting. (B) Experiments were performed as in panel A, and relative
ated with DMSO, NaB, niltubacin or tubacin were immunostained with
e). (D) HDAC6-depleted Raji cells were incubated on ice for 20 minutes
d with antibodies against α-tubulin (green) and acetylated tubulin (red).
ere incubated on ice for 20 minutes and then cells were immunostained
PI (blue). ***, P <0.001 versus DMSO; ns, not significant.
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nostat, romidepsin, and panobinostat [10]. In spite of ex-
cellent potency on shrinking tumors, these agents lead to
inevitable adverse effects sometimes. Thus, elucidating the
exact mediator responsible for the inhibitory effect on tu-
mors is obligated. It is reported that HDAC2 suppresses
the expression of p53, causing cell survival and insensitiv-
ity to chemotherapeutic agents [19,20]. In addition, loss of
HDAC5 restrains the cell proliferation of hepatocellular
carcinoma by regulation of p21 and cyclin D1, thereby
leading to cell cycle arrest and apoptosis [21]. In this sce-
nario, we revealed that HDAC6 did not affect the prolifer-
ation and cell cycle progression of Raji cells, which is
consistent with the results found in mouse embryonic
stem cells [13]. Regarding little cytotoxicity of HDAC6 in-
hibitors in BL cells, it would be interesting in the future to
investigate the efficiency of HDAC6 inhibitors combined
with genotoxic agents or radiotherapy for the manage-
ment of advanced BL.
It is believed that microtubule cytoskeleton is exquisitely
modulated to fulfill their distinct function, such as mitosis,
differentiation, directed cell movement, and vehicle trans-
port [22-24]. HDAC6 is identified as a microtubule-binding
protein, which regulates microtubule dynamics through
deacetylation of α-tubulin [12]. In addition, several other
HDAC6 substrates have been identified, including cortac-
tin, MAP7 domain-containing protein 3 (Mdp3), and heat
shock protein 90 (HSP-90) [25-27]. As microtubule dy-
namics is essential for the establishment of cell polarity,
turnover of focal adhesion, and cell motility, we concen-
trated on α-tubulin in this study. Our data revealed that
microtubule stability against cold-induced depolymerizing
condition was promoted in pharmacologically treated cells
other than in HDAC6-depleted cells, which was consistent
with the observation found in MCF-7 cells [28]. Taken to-
gether, these findings demonstrate that HDAC6 modulates
the acetylation level of α-tubulin, leading to chemokine
induced microtubule remodeling and directed move-
ment of BL cells, which provides the basis for pharmaco-




Tubacin (HDAC6 selective inhibitor) and NaB (a HDAC
inhibitor without activity on HDAC6) were purchased from
Santa Cruz Biotech (CA, USA). Niltubacin (deacetylase in-
active tubacin derivatives) was purchased from Abcam
(MA, USA). Antibodies against α-tubulin and acetylated
tubulin were purchased from Abcam (MA, USA). SDF-1α,
DAPI and propidium iodide (PI) were form Sigma
(MO, USA), and CellTiter-Glo luminescent cell viability
assay kit was from Promega (WI, USA). Fibronectin and
Transwell were purchased from BD Biosciences (NJ, USA)and Corning (MA, USA), respectively. SiRNAs targeting lucif-
erase (control) and HDAC6 were synthesized by Invitrogen
(Beijing, China).
Cell culture and transfection
Human Burkitt ? s lymphoma Raji and Namalwa cells were
purchased from the American Type Culture Collection
(ATCC), and maintained in the RPMI1640 medium sup-
plemented with 10% FBS. SiRNAs were transfected into
cells by using lipofectamine 2000 (Invitrogen) according
to the manufacturer ? s instruction.
Cell proliferation assay
Cells were seeded at 6000 cells/well 12 hours prior to
DMSO, NaB, or tubacin exposure. At the indicated time,
cell viability was determined by CellTiter-Glo lumines-
cent cell viability assay kit according to the manufac-
ture ? s protocol.
Immunoblotting
Cells were lyzed in cell lysis buffer containing 1% Triton
X-100, 150 mM NaCl, and 50 mM Tris. Proteins were
separated by 10% SDS-PAGE gel electrophoresis, and
then transferred onto PVDF membranes. The mem-
branes were blocked in Tris-buffered saline containing
5% fat-free dry milk and 0.2% Tween 20. After incuba-
tion with primary antibodies, the membranes were incu-
bated with horseradish peroxidase-conjugated secondary
antibodies. The proteins of interest were detected with
enhanced chemiluminescence detection reagent accord-
ing to the manufacturer ? s instructions.
Cell cycle progression analysis
Raji cells treated with DMSO, NaB (1 μM), or tubacin
(1 μM) were collected and washed twice with ice-cold
phosphate-buffered saline (PBS). Then cells were fixed
with 70% ethanol at 4?C for 24 hours. After twice wash
with PBS, cells were incubated with propidium iodide
(PI)/RNase A solution for 30 minutes. Samples were ex-
amined with a BD FACS Calibur Flow Cytometer.
Cell motility assays
Cell motility assays were carried out as described [29]
with minor modification. For cell migration assay, Raji
cells or Namalwa cells suspended in serum free medium
were plated into inserts, and for cell invasion assay, cells
suspended in serum free medium were plated into in-
serts which were precoated with Fibronectin (50 ng/ml)
for overnight. DMSO, NaB (1 μM), or tubacin (1 μM) was
added to the inserts, and then the inserts were placed in a
24-well plate containing the serum free medium supple-
mented with SDF-1α (100 ng/ml). 12 hours later, cells in
the lower chambers were analyzed by a BD FACS Calibur
Flow Cytometer.
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Prior to SDF-1α (100 ng/ml) stimulation, Raji cells were
treated with DMSO, NaB (1 μM), or tubacin (1 μM)
for 3 hours. Then cells were plated into a 96-well plate
which were precoated with Fibronectin (50 ng/ml) to allow
cell adherence for 30 minutes. Subsequently cells were
washed with PBS three times to remove the non-adherent
cells, and adherent cells were measured by CellTiter-Glo
luminescent cell viability assay kit.
Immunofluorescence microscopy
Immunofluorescence staining was performed as described
[30]. In brief, cells grown on glass coverslips were fixed
with 4% paraformaldehyde for 30 minutes. Cells were
washed for three times with PBS, followed by incubation
with 2% bovine serum albumin for 20 minutes. Then cells
were sequentially incubated with primary antibodies and
fluorescein-conjugated secondary antibodies. The nuclei
were counterstained with DAPI. Coverslips were mounted
with 90% glycerol in PBS and imaged with a Zeiss fluores-
cence microscope.
Microtubule stability analysis
Raji cells were incubated with DMSO, NaB, niltubacin or
tubacin or transfected with HDAC6 siRNA for 24 hours,
then cells were incubated on ice for 0 or 20 minutes. Cells
were then fixed and immunostained with antibodies against
α-tubulin and acetylated tubulin.
Statistical analysis
All data were derived from three independent experi-
ments, and expressed as means ? SD. Student ? s t-test and
one-way analysis of variance (ANOVA) were performed
for statistical analysis. P value < 0.05 indicates statistical
significance.
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